Sarepta Therapeutics

Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD
Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD
Endpoints
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
golodirsen
Flag link:
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
Endpoints
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
These 3 Biotechs Just Crushed Analyst Expectations
These 3 Biotechs Just Crushed Analyst Expectations
Motley Fool
biotech
earnings
Sarepta Therapeutics
Biogen
Gilead Sciences
Flag link:
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Endpoints
Allergan
Sarepta Therapeutics
Doug Ingram
Flag link:
Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Endpoints
Sarepta Therapeutics
Genethon
Duchenne Muscular Dystrophy
gene therapy
China
Pluristem
Flag link:
After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
Endpoints
Sarepta Therapeutics
Chris Garabedian
Xontogeny
startups
Flag link:
How Much Would Sarepta Therapeutics Fetch in a Buyout?
How Much Would Sarepta Therapeutics Fetch in a Buyout?
Motley Fool
Sarepta Therapeutics
M&A
Flag link:
Sarepta Therapeutics May Attract Activist Attention
Sarepta Therapeutics May Attract Activist Attention
TheStreet.com
Sarepta Therapeutics
activists
Flag link:
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
TheStreet.com
Sarepta Therapeutics
Sanofi
M&A
Pharma CEOs
Ed Kaye
Flag link:
Biotech Movers: Sarepta, Paratek, PDL BioPharma
Biotech Movers: Sarepta, Paratek, PDL BioPharma
TheStreet.com
Sarepta Therapeutics
Exondys 5
Paratek
omadacycline
PDL Biopharma
patents
Merck
Keytruda
Flag link:
Sarepta chief hands over CMO role to former Regeneron exec
Sarepta chief hands over CMO role to former Regeneron exec
Bizjournals.com
Sarepta Therapeutics
Regeneron
CMOs
Flag link:
Payor Re-Evaluation On Exondys Positive For Sarepta
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
Sarepta Therapeutics reports 4Q loss
Sarepta Therapeutics reports 4Q loss
Yahoo/AP
Sarepta Therapeutics
earnings
Flag link:
How the newest Duchenne biotechs are getting a boost from patient groups
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Flag link:
Sarepta Sells Priority Review Voucher for $125M
Sarepta Sells Priority Review Voucher for $125M
Investopedia
Sarepta Therapeutics
Gilead Sciences
priority review
FDA
Flag link:
Sarepta eyes a different approach to Duchenne: gene therapy
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
Flag link:
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
The Best Biopharma CEOs of 2016 Are...
The Best Biopharma CEOs of 2016 Are...
TheStreet.com
Pharma CEOs
Ken Frazier
Merck
David Hung
Medivation
Scott Jackson
Celator Pharmaceuticals
Ed Kaye
Sarepta Therapeutics
Mike Morrissey
Exelixis
Flag link: